Newsroom

During Advanced Therapies Week (ATW) 2024, Drug Discovery World heard from attendees and experts, including ScaleReady's Josh Ludwig, about the obstacles the sector needs to overcome to succeed. 

The high cost of CAR-T therapy has been a major barrier to its widespread adoption. However, a new study suggests that a more standardized, modular production approach could help to reduce costs and make this life-saving treatment more accessible to patients.

The gears driving Industry 4.0 continue to catalyze many aspects of production in all industries. With pharma being traditionally known for lagging somewhat in this uptake, we gathered four experts to discuss what’s changed, what’s changing, and what the future looks like for Industry 4.0 in pharma manufacturing.

In this Genetic Engineering & Biotechnology News article, "Downstream Trends and Challenges," the author discusses the increasing complexity and challenges facing manufacturers today. ScaleReady is mentioned as a joint venture designed to better serve cell therapy developers with scaleable, flexible platforms from established partners.

Pharma's Almanac asked industry experts, including ScaleReady's Global Director Josh Ludwig, their thoughts on the most significant regulatory decisions or guidance on the horizon for 2024. Josh discusses establishing more comprehensive and flexible guidelines for CGTs that will provide the clarity needed to enable creative, high-throughput manufacturing strategies.

Josh Ludwig, Global Director of ScaleReady, joins Pharma's Almanac and biopharma industry experts to discuss the most consequential events and results of 2023. Josh reviews how investment setbacks have instigated a pivotal paradigm shift in cell therapy manufacturing this year.

Before investing in advanced tech, manufacturers must fully understand AI and automation in the unique context of CGT production. Josh Ludwig, Global Director, ScaleReady writes about the importance of simplifying existing CGT manufacturing processes before integrating AI and automation, ensuring a smooth transition.

To meet rising patient demand, the cell and gene therapy industry must rapidly scale up production through advancements in automation, talent acquisition, and supply chain management. Genetic Engineering & Biotechnology News discusses advancements in cell therapy industry growth, including the ScaleReady joint venture.

Technology is transforming healthcare, with a major focus on the development of precision medicine. Josh Ludwig, Global Director of ScaleReady, discusses the implications of automation and AI in cell therapy.

The Medicine Maker gathered four experts, including ScaleReady's Josh Ludwig, to discuss what’s changed, what’s changing, and what the future looks like for Industry 4.0 in pharma manufacturing, knowing the industry traditionally lags somewhat in this uptake.

Cell and gene therapy is a young biopharma sector approaching adolescence. As more companies transition from R&D to commercialization, has it got the balance right on diversity in senior leadership?